Lab
Advanced Molecular Diagnostics, LLC
Advanced Molecular Diagnostics, LLC was paid $39.84M by Medicaid between Jan 2018 and Nov 2024, across 56 billing codes. Its largest line is 81408, — 14% of everything it billed.
33Billing provider infoADVANCED MOLECULAR DIAGNOSTICS, LLC
MONTVALE, NJ 07645
MONTVALE, NJ 07645
33aNPI1790023547assigned 01/29/2013
33bProvider typeClinical Medical Laboratory
28Total paid$39.84M
24GClaims214,620
24DCodes billed56
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New Jersey
Rank by total paid#8 of 122
Median peer was paid$1.29M
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,414 | $13.86M | |
| 2019 | 11,207 | $6.85M | |
| 2020 | 10,809 | $1.58M | |
| 2021 | 15,701 | $2.80M | |
| 2022 | 81,770 | $6.96M | |
| 2023 | 50,924 | $4.72M | |
| 2024incomplete | 18,795 | $3.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81408 | 14% | 5,919 | 4,855 | $5.74M | |
| 81406 | 13% | 7,467 | 6,061 | $5.31M | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 13% | 51,940 | 16,544 | $5.14M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 9.7% | 6,900 | 5,977 | $3.86M |
| 81162 | 6.5% | 2,328 | 2,058 | $2.60M | |
| 81405 | 5.4% | 7,418 | 6,230 | $2.15M | |
| 81255 | 3.5% | 5,214 | 4,571 | $1.38M | |
| 81211 | 3.2% | 715 | 636 | $1.26M | |
| 81404 | 3.1% | 6,765 | 5,641 | $1.24M | |
| 81407 | 2.2% | 3,340 | 2,815 | $891K | |
| 81321 | 1.9% | 2,745 | 2,447 | $772K | |
| 81298 | 1.8% | 2,549 | 2,252 | $721K |
44 more codes
| 81317 | 1.6% | 2,497 | $650K | |
| 81292 | 1.6% | 2,473 | $640K | |
| 81200 | 1.5% | 4,221 | $597K | |
| 81201 | 1.5% | 2,269 | $594K | |
| 81251 | 1.5% | 3,979 | $591K | |
| 81209 | 1.5% | 4,298 | $588K | |
| 81290 | 1.5% | 4,279 | $584K | |
| 81260 | 1.5% | 4,054 | $583K | |
| 81295 | 1.3% | 2,563 | $534K | |
| 81242 | <1% | 4,206 | $390K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 28,542 | $372K |
| 81364 | <1% | 2,951 | $335K | |
| 81307 | <1% | 1,562 | $286K | |
| 81213 | <1% | 607 | $280K | |
| 81329 | <1% | 4,260 | $269K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,770 | $251K |
| 81257 | <1% | 4,235 | $249K | |
| 81403 | <1% | 2,661 | $161K | |
| 81243 | <1% | 1,676 | $152K | |
| 81252 | <1% | 3,465 | $139K | |
| 81205 | <1% | 2,700 | $85K | |
| 81226 | <1% | 625 | $68K | |
| 81401 | <1% | 545 | $52K | |
| 81254 | <1% | 3,365 | $48K | |
| 81225 | <1% | 725 | $43K | |
| 81323 | <1% | 1,433 | $41K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,340 | $40K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,343 | $37K |
| 81336 | <1% | 204 | $24K | |
| 81418 | <1% | 332 | $19K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 1,535 | $15K |
| 81300 | <1% | 1,370 | $11K | |
| 81297 | <1% | 1,373 | $11K | |
| 81328 | <1% | 386 | $10K | |
| 81294 | <1% | 1,372 | $10K | |
| 81203 | <1% | 965 | $9K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 80 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 360 | $3K |
| 81227 | <1% | 18 | $874.53 | |
| 87631 | <1% | 16 | $533.75 | |
| 87486 | <1% | 13 | $210.54 | |
| 87581 | <1% | 13 | $210.54 | |
| 81319 | 0% | 591 | $0.00 | |
| 81443 | 0% | 48 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialUMANSKY, PABLO (CEO)